Clinical review report Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

Common drug review clinical review report.

Common drug review clinical review report

Language:

English

Subjects (All):

Hypoglycemic agents.

Physical Description:

1 online resource (164 pages) : illustrations.

Edition:

First edition.

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017.

Summary:

The objective of this review was to perform a systematic review of the beneficial and harmful effects of lixisenatide (Adlyxine) for the treatment of adults with type 2 diabetes in combination with a basal insulin (alone or with metformin).

Contents:

Abbreviations

Executive Summary

Introduction

Disease Prevalence and Incidence

Standards of Therapy

Drug

Objectives and Methods

Objectives

Methods

Results

Findings from the Literature

Included Studies

Exposure to Study Treatments

Critical Appraisal

Efficacy

Harms

Discussion

Summary of Available Evidence

Interpretation of Results

Conclusions

Appendix 1. Patient Input Summary

Appendix 2. Literature Search Strategy

Appendix 3. Excluded Studies

Appendix 4. Detailed Outcome Data

Appendix 5. Validity of Outcome Measures

Appendix 6. Summary of the ELIXA Trial

Appendix 7. Summary of GETGOAL - O

References.

Notes:

Includes bibliographical references.

Description based on publisher supplied metadata and other sources.